AU5953894A - Bisphosphonate/estrogen therapy for treating and preventing bone loss - Google Patents

Bisphosphonate/estrogen therapy for treating and preventing bone loss

Info

Publication number
AU5953894A
AU5953894A AU59538/94A AU5953894A AU5953894A AU 5953894 A AU5953894 A AU 5953894A AU 59538/94 A AU59538/94 A AU 59538/94A AU 5953894 A AU5953894 A AU 5953894A AU 5953894 A AU5953894 A AU 5953894A
Authority
AU
Australia
Prior art keywords
bisphosphonate
estrogen
bone
bone loss
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59538/94A
Other languages
English (en)
Inventor
Donna T Whiteford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5953894A publication Critical patent/AU5953894A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU59538/94A 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss Abandoned AU5953894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
PCT/US1993/012302 WO1994014455A1 (fr) 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
US996418 1997-12-22

Publications (1)

Publication Number Publication Date
AU5953894A true AU5953894A (en) 1994-07-19

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59538/94A Abandoned AU5953894A (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss

Country Status (5)

Country Link
EP (1) EP0675723A4 (fr)
JP (1) JPH08505142A (fr)
AU (1) AU5953894A (fr)
CA (1) CA2151240A1 (fr)
WO (1) WO1994014455A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687744B2 (en) * 1993-05-15 1998-03-05 Riemser Arzneimittel Ag More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
JPH10506638A (ja) * 1995-05-12 1998-06-30 メルク エンド カンパニー インコーポレーテッド アレンドロネート又はその塩の投与による歯喪失の予防
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
EP0939624B1 (fr) * 1996-05-17 2003-12-17 Merck & Co., Inc. Formulation de bisphosphonate efferverscente
EP1378234A1 (fr) * 1996-05-17 2004-01-07 MERCK & CO. INC. Formulation de bisphosphonate effervescente
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
WO1998023274A1 (fr) * 1996-11-25 1998-06-04 Merck & Co., Inc. Agents androgene et bisphosphonique coadministres pour traiter des maladies
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US6555529B1 (en) * 1997-12-25 2003-04-29 Toray Industries, Inc. Remedies for intramedullary diseases
BR9915927A (pt) 1998-12-04 2001-08-21 Roche Diagnostics Gmbh Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis
CA2370769A1 (fr) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Administration regulee de bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
FR2803521B1 (fr) 2000-01-12 2002-10-25 Ceva Sante Animale Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
SK9862003A3 (en) 2001-02-06 2004-02-03 Royal Alexandra Hosp Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
EP2172192A1 (fr) 2001-12-24 2010-04-07 Teva Pharmaceutical Industries Ltd. Forme de dosage dotée d'un comprimé central d'ingrédient actif insérée dans un corps annulaire comprimé de poudre de matériau granulaire et procédé et outillage pour la produire
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
KR101315925B1 (ko) * 2005-10-27 2013-10-08 토멘 메디칼 아게 치과용 임플란트 및 그의 제조 방법
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4029499A1 (de) * 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687744B2 (en) * 1993-05-15 1998-03-05 Riemser Arzneimittel Ag More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent

Also Published As

Publication number Publication date
CA2151240A1 (fr) 1994-07-07
EP0675723A1 (fr) 1995-10-11
JPH08505142A (ja) 1996-06-04
EP0675723A4 (fr) 1998-08-05
WO1994014455A1 (fr) 1994-07-07

Similar Documents

Publication Publication Date Title
AU5953894A (en) Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5972913A (en) Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0635270B1 (fr) Hormone parathyroide et raloxifène pour augmenter la masse d'os
US20040097468A1 (en) Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US6376477B2 (en) Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
AU743121B2 (en) Androgenic and bisphosphonic agents coadministered to treat diseases
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
MXPA96004968A (en) Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis
AU9745901A (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU3574799A (en) Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis
Forde Pharmacological Intervention in the Treatment of Osteoporosis: What's Old and What's New